ELAN vs. HLN: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ELAN and HLN, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ELAN is a standard domestic listing, while HLN trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | ELAN | HLN |
|---|---|---|
| Company Name | Elanco Animal Health Incorporated | Haleon plc |
| Country | United States | United Kingdom |
| GICS Sector | Health Care | Consumer Staples |
| GICS Industry | Pharmaceuticals | Personal Care Products |
| Market Capitalization | 8.85 billion USD | 43.48 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | September 20, 2018 | July 25, 2022 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of ELAN and HLN by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ELAN | HLN |
|---|---|---|
| 5-Day Price Return | 8.07% | 1.98% |
| 13-Week Price Return | 38.92% | -10.35% |
| 26-Week Price Return | 48.79% | -6.08% |
| 52-Week Price Return | 36.06% | -5.03% |
| Month-to-Date Return | 30.19% | -1.25% |
| Year-to-Date Return | 47.07% | -5.94% |
| 10-Day Avg. Volume | 7.61M | 18.28M |
| 3-Month Avg. Volume | 6.03M | 18.67M |
| 3-Month Volatility | 46.30% | 16.25% |
| Beta | 1.67 | 0.35 |
Profitability
Return on Equity (TTM)
ELAN
6.74%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
ELAN’s Return on Equity of 6.74% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
HLN
3.26%
Personal Care Products Industry
- Max
- 31.59%
- Q3
- 20.42%
- Median
- 11.01%
- Q1
- 3.26%
- Min
- -18.42%
HLN’s Return on Equity of 3.26% is on par with the norm for the Personal Care Products industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
ELAN
9.68%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
ELAN’s Net Profit Margin of 9.68% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.
HLN
12.84%
Personal Care Products Industry
- Max
- 15.12%
- Q3
- 12.06%
- Median
- 9.26%
- Q1
- 5.50%
- Min
- -0.40%
A Net Profit Margin of 12.84% places HLN in the upper quartile for the Personal Care Products industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ELAN
16.21%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
ELAN’s Operating Profit Margin of 16.21% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
HLN
19.64%
Personal Care Products Industry
- Max
- 19.80%
- Q3
- 17.96%
- Median
- 13.14%
- Q1
- 7.58%
- Min
- -4.25%
An Operating Profit Margin of 19.64% places HLN in the upper quartile for the Personal Care Products industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ELAN | HLN |
|---|---|---|
| Return on Equity (TTM) | 6.74% | 3.26% |
| Return on Assets (TTM) | 3.30% | 1.58% |
| Net Profit Margin (TTM) | 9.68% | 12.84% |
| Operating Profit Margin (TTM) | 16.21% | 19.64% |
| Gross Profit Margin (TTM) | 54.73% | 60.75% |
Financial Strength
Current Ratio (MRQ)
ELAN
2.60
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
ELAN’s Current Ratio of 2.60 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
HLN
0.87
Personal Care Products Industry
- Max
- 4.26
- Q3
- 2.61
- Median
- 1.74
- Q1
- 1.13
- Min
- 0.76
HLN’s Current Ratio of 0.87 falls into the lower quartile for the Personal Care Products industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
ELAN
0.62
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
ELAN’s Debt-to-Equity Ratio of 0.62 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
HLN
0.53
Personal Care Products Industry
- Max
- 1.13
- Q3
- 0.63
- Median
- 0.26
- Q1
- 0.04
- Min
- 0.00
HLN’s Debt-to-Equity Ratio of 0.53 is typical for the Personal Care Products industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ELAN
3.08
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
ELAN’s Interest Coverage Ratio of 3.08 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
HLN
8.00
Personal Care Products Industry
- Max
- 96.53
- Q3
- 59.91
- Median
- 22.25
- Q1
- 7.85
- Min
- -1.93
HLN’s Interest Coverage Ratio of 8.00 is positioned comfortably within the norm for the Personal Care Products industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ELAN | HLN |
|---|---|---|
| Current Ratio (MRQ) | 2.60 | 0.87 |
| Quick Ratio (MRQ) | 1.18 | 0.63 |
| Debt-to-Equity Ratio (MRQ) | 0.62 | 0.53 |
| Interest Coverage Ratio (TTM) | 3.08 | 8.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ELAN
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
ELAN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
HLN
0.72%
Personal Care Products Industry
- Max
- 4.08%
- Q3
- 2.46%
- Median
- 1.82%
- Q1
- 0.83%
- Min
- 0.00%
HLN’s Dividend Yield of 0.72% is in the lower quartile for the Personal Care Products industry. This suggests the company’s strategy likely favors retaining earnings for growth over providing a high dividend income.
Dividend Payout Ratio (TTM)
ELAN
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
ELAN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
HLN
954.40%
Personal Care Products Industry
- Max
- 207.61%
- Q3
- 115.17%
- Median
- 69.37%
- Q1
- 47.71%
- Min
- 0.00%
At 954.40%, HLN’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Personal Care Products industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | ELAN | HLN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.72% |
| Dividend Payout Ratio (TTM) | 0.00% | 954.40% |
Valuation
Price-to-Earnings Ratio (TTM)
ELAN
20.27
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
ELAN’s P/E Ratio of 20.27 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
HLN
22.09
Personal Care Products Industry
- Max
- 55.49
- Q3
- 36.75
- Median
- 26.49
- Q1
- 22.40
- Min
- 11.12
In the lower quartile for the Personal Care Products industry, HLN’s P/E Ratio of 22.09 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
ELAN
1.96
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
ELAN’s P/S Ratio of 1.96 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
HLN
2.84
Personal Care Products Industry
- Max
- 5.35
- Q3
- 2.83
- Median
- 2.07
- Q1
- 1.13
- Min
- 0.00
HLN’s P/S Ratio of 2.84 is in the upper echelon for the Personal Care Products industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
ELAN
1.05
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
ELAN’s P/B Ratio of 1.05 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
HLN
2.11
Personal Care Products Industry
- Max
- 7.32
- Q3
- 5.26
- Median
- 2.93
- Q1
- 1.84
- Min
- 1.14
HLN’s P/B Ratio of 2.11 is within the conventional range for the Personal Care Products industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ELAN | HLN |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 20.27 | 22.09 |
| Price-to-Sales Ratio (TTM) | 1.96 | 2.84 |
| Price-to-Book Ratio (MRQ) | 1.05 | 2.11 |
| Price-to-Free Cash Flow Ratio (TTM) | 21.14 | 14.81 |